tixagevimab   Click here for help

GtoPdb Ligand ID: 11330

Synonyms: AZD8895 | COV2-2196
Compound class: Antibody
Comment: Tixagevimab is a monoclonal antibody against the surface spike protein of SARS-CoV-2 [1]. It was developed by AstraZeneca. This mAb blocks spike binding to ACE2 and prevents infection in animals. Tixagevimab is designed to be a long-acting agent, and in combination with cilgavimab, is proposed as a therapeutic for those people who are likely to respond poorly to SARS-CoV-2 vaccines, or who cannot be vaccinated for any reason, including those who are immunocompromised.
Bioactivity Comments
Binds to the trimeric S2Pecto synthetic spike protein mimic with an EC50 of 10.2 ng/ml [1].
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
CoV Spike glycoprotein SARS-CoV-2 Antibody Binding - - - 1